seekingalpha.com /1 month ago

Alcon wins approval of OTC Brytly eye drops

Read source
seekingalpha.com /1 week ago

Alcon Q3 2026 Earnings Preview

Read source
medcitynews.com /4 weeks ago

Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition

Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a...

Read source
pharmexec.com /1 month ago

<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...

Read source
fortworthbusiness.com /3 weeks ago

The World’s Next Breakthrough in Eye Care Isn’t Just Innovation. It’s Capacity.

Few things are more fundamental to human potential than the ability to see. Sight helps us connect with others, navigate the world and live independently. Yet, a gap between what i...

Read source
biopharmadive.com /6 days ago

J&J bets $2.2B on Ollin’s vision loss drug

The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.